{
    "clinical_study": {
        "@rank": "79103", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants previously enrolled in Study CCL09191E will receive momelotinib for up to 4 years."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants previously enrolled in Study YM387-II-02 will receive momelotinib for up to 4 years."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years."
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label study is to determine the long-term safety and tolerability of momelotinib\n      in previously enrolled study participants with primary myelofibrosis (PMF),\n      post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia\n      myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who\n      have tolerated and achieved stable disease or better with momelotinib treatment while\n      enrolled in a previous clinical trial."
        }, 
        "brief_title": "Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Myelofibrosis", 
            "Post-Polycythemia Vera Myelofibrosis", 
            "Post-Essential Thrombocythemia Myelofibrosis", 
            "Polycythemia Vera", 
            "Essential Thrombocythemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Thrombocythemia, Essential", 
                "Thrombocytosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Currently enrolled in study CCL0910E, YM387-II-02, or successfully completed\n\n          -  Able to comprehend and willing to sign informed consent form\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to momelotinib, its metabolites, or formulation excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124746", 
            "org_study_id": "GS-US-352-1154", 
            "secondary_id": "2013-004476-36"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3"
            ], 
            "description": "Momelotinib tablets administered orally once daily", 
            "intervention_name": "Momelotinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "GS-0387", 
                "CYT387"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary Myelofibrosis", 
            "Post Polycythemia Vera Myelofibrosis", 
            "Post Essential Thrombocythemia  Myelofibrosis", 
            "Polycythemia Vera", 
            "Essential Thrombocythemia", 
            "blood disorders"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parkville", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Helen Collins, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This composite endpoint will measure the long-term safety and tolerability profile of momelotinib; safety information will include safety data collected after the first dose of momelotinib from the previous study.", 
            "measure": "The incidence and severity of adverse events and clinical laboratory abnormalities", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124746"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival (OS) is defined as the interval from the first dose of momelotinib on the previous study until death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Progression-free survival (PFS) is defined as the interval from the first dose of momelotinib on the previous study until the first documentation of definitive progressive disease or death due to any cause.\nProgressive disease for Cohorts 1 & 2 is defined as leukemic transformation, increase in peripheral blood blast for at least 8 weeks, or progressive splenomegaly.\nProgressive disease for Cohort 3 is defined as the interval from the first dose of momelotinib on the previous study until transformation into post-PV MF, post-ET MF, myelodysplastic syndrome (MDS), acute leukemia, or PV (for the ET subgroup).", 
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Leukemia-free survival is defined as the interval from the first dose of momelotinib on the previous study until the first documented leukemic transformation or death from any cause.", 
                "measure": "Leukemia-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Rate of red blood cell (RBC) transfusion is defined as the average number of RBC units per subject month from the first dose of momelotinib on the previous study during the study period.", 
                "measure": "Rate of RBC transfusion", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Duration of splenic response is defined as the interval from the first onset of splenic response (in the previous study or this study) to loss of splenic response for \u2265 4 weeks or death from any cause.\nSplenic response is defined as:\n> 50% reduction in palpable splenomegaly of a spleen that is \u2265 10 cm below the left costal margin (LCM) at baseline or\na spleen becomes not palpable, that is palpable at > 5 cm below the LCM at baseline", 
                "measure": "Duration of splenic response (Cohorts 1 and 2 only)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Duration of transfusion independence response is defined as the interval from the first onset date of transfusion independence (in the previous study or this study) to the earliest onset date of transfusion dependence or death from any cause for participants who are transfusion dependent at baseline.\nTransfusion independence is defined as absence of RBC transfusions for \u2265 8 weeks.", 
                "measure": "Duration of transfusion independence response (Cohorts 1 and 2 only)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Duration of anemia response is defined as the interval from the first onset of anemia response to the earliest date of loss of anemia response which persists for at least 4 weeks, or death from any cause\nAnemia response is defined as:\n\u2265 2g/dL increase in hemoglobin, if transfusion independent and with hemoglobin level of < 10g/dL at baseline\nAchieving transfusion independence for \u2265 8 weeks, if transfusion dependent at baseline", 
                "measure": "Duration of anemia response (Cohorts 1 and 2 only)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }, 
            {
                "description": "Confirmed and unconfirmed overall response rate (ORR) are defined as:\nConfirmed ORR: proportion of participants with onset of response in the previous study with the 12 week confirmation reached during this study\nUnconfirmed ORR: proportion of participants with PV or ET with onset of response in the previous study that lasts for at least 4 weeks", 
                "measure": "Overall response rate (Cohort 3 only)", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 years"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}